Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton, Dickinson and Co.

Becton Dickinson said on Thursday that it will increase domestic production of medical syringes.

Becton Dickinson to increase domestic production of syringes

Becton, Dickinson and Company (BD) experienced weak growth in China, with a decline of 5.3% year-over-year. BD's major challenges, including the Alaris pump and Covid comparisons, are starting to normalize. The stock price is undervalued, leading to an upgrade in rating from 'Hold' to 'Buy' with a fair value of $250 per share.

Becton, Dickinson And Company: Growth Starts To Normalize (Rating Upgrade)

Becton Dickinson beat first-quarter profit estimates and raised its full-year earnings forecast on Thursday as it benefits from strong demand for its surgical equipment.

Becton Dickinson lifts 2024 profit forecast on surgical devices strength

Becton, Dickinson and Company has underperformed the market and healthcare sector in recent years. The company's balance sheet has improved significantly which I believe will allow for increased returns of capital to shareholders going forward. BDX's recent guidance for FY 2024 has lowered earnings expectations, but the company has a history of beating consensus estimates.

Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play

In an interview with CNBC's Jim Cramer, Becton Dickinson CEO Tom Polen described how the medical device manufacturer's new technology can save hospitals money.

Becton Dickinson CEO describes how new technology helps hospitals fight inflated operating costs

Becton Dickinson said on Thursday the U.S. Food and Drug Administration (FDA) had cleared its less invasive blood collection device.

US FDA clears Becton Dickinson's blood collection device

Acutus Medical

Eagle Pharmaceuticals

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That Could Blast Off This Quarter - Acutus Medical (NASDAQ:AFIB), Becton Dickinson (NYSE:BDX)

Becton, Dickinson, and Company is a healthcare company with strong fundamentals and a history of dividend growth. The company has shown robust execution of its 2025 strategy, positioning it for sustained growth and innovation in the medical technology space. However, there are risks to the investment, including slower EPS growth, competition, and a lack of margin of safety in the current valuation.

Following The Q4 Results, Becton, Dickinson and Company Is Still A Hold

Disney

Tesla

U.S. equities fell midday ahead of comments from Fed Chair Jerome Powell that could offer clues about the future of monetary policy. The Dow, S&P 500, and Nasdaq were all lower.

Midday Movers: Disney Rises, Tesla and Becton Dickinson Fall

AbbVie

Automatic Data Processing

American Electric Power Company

A. O. Smith

Amphenol

Black Hills

Brown & Brown

Evergy Inc

Gorman-Rupp

Lincoln Electric Hlds

Lockheed Martin

Visa and Exxon Mobil announced dividend increases in October, with Visa increasing its dividend by 15.6% and Exxon Mobil increasing its dividend by 4.4%. Several companies, including AbbVie, American Electric Power, and McDonalds, met or exceeded dividend increase predictions in October. Dividend growth slowed for companies like Amphenol, Black Hills, and Tompkins Financial due to various factors such as the current economic slowdown and flat or lower earnings.

Becton, Dickinson And HP Among 13 Companies Announcing Annual Dividend Increases In The First Half Of November

Becton, Dickinson and Company is a global healthcare company specializing in medical supplies, devices, and diagnostic products. BDX saw solid growth in Q3 driven by strong demand for pharmacy automation systems and medical devices. The company raised its revenue guidance for FY23 and expects continued profitability improvement in the near future.

Becton, Dickinson Stock Is A Hold, Here's Why

Becton Dickinson beat Wall Street estimates for third-quarter profit on Thursday, helped by strong demand for its drug delivery devices and surgical equipment.

Becton Dickinson beats quarterly profit estimates on strong medical device sales

Shares of Becton Dickinson rose to their highest level since 2020 after the FDA gave 501(k) clearance to Becton Dickinson's updated BD Alaris Infusion System.

Becton Dickinson Shares Jump After FDA Decision on Its Infusion System

Shares of Becton Dickinson hit an all-time high on Monday and were last up 6.1% after the medical device maker received U.S. Food and Drug Administration clearance late on Friday for the market return of its drug infusion system.

Becton Dickinson shares hit record high after US FDA clears return of drug infusion system

The company filed a 501(k) resubmission for its new BD Alaris Infusion System two years ago. The company said it will begin immediately distributing the new Alaris Infusion System, and will remediate older versions of the device.

Why Shares of Becton, Dickinson Rose Monday

Becton, Dickinson and Company has seen another year of relative stagnation. Following the spinoff of the Diabetes Care unit, sales and earnings have taken a small setback. Valuations remain full at around 20 times adjusted earnings amidst some leverage still being apparent and with structural growth hard to come by.

Becton, Dickinson and Company: Still Not Very Healthy

I expect Becton, Dickinson and Company to beat 2H23 estimates due to reduced expectations and margin improvements. BDX's management has made progress in SKU rationalizations, workforce reduction, and enhancing the company's structural margin profile. The stable operating environment, procedure volume recovery, and hospital capital spending appetite support revenue growth for BDX.

Becton, Dickinson: Business Should Beat H2 2023 Expectations

Becton Dickinson stock (NYSE: BDX) has seen a 7% fall this year, faring better than the broader S&P500 index, down 17%.

Is There More Room For Growth In Becton Dickinson Stock?

Becton Dickinson & Co. stock BDX, -0.55% slid 1.3% in premarket trade Thursday, after the medical tech and diagnostics company beat estimates for its fiscal fourth quarter but offered guidance that lagged. The Franklin Lakes, N.J.

Becton Dickinson stock down 1.3% premarket as Q4 earnings beat tempered by soft fiscal 2023 guidance

Becton Dickinson & Co. BDX, -0.55% said Thursday its board has approved a 4.6% increase in its quarterly dividend to 91 cents a share. The medical tech and diagnostics company said the new dividend is payable Dec. 30 to shareholders of record as of Dec. 9.

Becton Dickinson raises quarterly dividend by 4.6% to 91 cents a share

Eli Lilly

There is more to the comparison, and in the sections below, we discuss why we believe BDX stock will offer better returns than LLY stock in the next three years.

This Healthcare Company Is Likely To Offer Better Returns Over Eli Lilly Stock

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Becton Dickinson (BDX) Crossed Above the 20-Day Moving Average: What That Means for Investors

Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q1 2022 Results - Earnings Call Transcript

Becton Dickinson and Co BDX reported Q1 FY22 revenues of $4.9 billion, down 6% Y/Y (-5.9% on a currency-neutral basis), better than the consensus of $4.76 billion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Becton Dickinson Q1 Earnings Top Estimates, Raises FY22 Guidance On Higher COVID-19 Related Sales

Becton Dickinson (BDX) delivered earnings and revenue surprises of 27.27% and 4.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A Stock (BDXA)